CD8A and neoplasm: To address this, 2DG-loaded PLGA nanoparticles (2DG-PLGA-NPs) were developed, which effectively promote tumor cell apoptosis, enhance IFN-γ production in CD8+ T cells, and resist anti-PD-1 resistance when combined with sorafenib or anti-PD1 (153).